Tabilo Valenzuela Paz Beatriz, Flores Balter Gabriela, Saint-Pierre Contreras Gustavo, Conei Valencia Daniel, Moreno Calderón Catalina, Bohle Venegas Constanza, Guajardo Rivera Marcia, Silva Ojeda Francisco, Vial Covarrubias Maria Jesus
Servicio de Laboratorio Clínico, Hospital Clínico Universidad de Chile, Santiago 8380000, Chile.
Programa de Doctorado en Ciencias Morfológicas, Universidad de La Frontera, Temuco 4811230, Chile.
Life (Basel). 2022 Apr 5;12(4):534. doi: 10.3390/life12040534.
In December 2019, a case of atypical pneumonia was reported in Wuhan, China. It was named COVID-19 and caused by SARS-CoV-2. In a few months, scientific groups around the world developed vaccines to reduce the disease's severity. The objective was to evaluate the humoral and cellular immune response post immunization with three different vaccination schedules administered in Chile until January 2022. Sixty volunteers were recruited with a three-dose schedule, who had no history of infection nor close contact with a positive patient. IgG against the spike antigenic domain was detected, and the neutralization capacity against two groups of variants, Original/Alpha and Beta/Gamma, was also measured. Finally, the cellular response with interferon release was measured through IGRA. Results showed that there were significant differences in the neutralizing antibodies for the original and alpha variant when comparing three Comirnaty doses with Coronavac and Vaxzevria. A high number of reactive subjects against the different SARS-CoV-2 variants, alpha, gamma, and delta, were observed, with no significant differences between any of the three schemes, confirming the existence of a cellular immune response against SARS-CoV-2. In conclusion, the three vaccine schemes generated a cellular immune response in these volunteers.
2019年12月，中国武汉报告了一例非典型肺炎病例。它被命名为COVID-19，由SARS-CoV-2引起。在几个月内，世界各地的科研团队研发出了减轻该疾病严重程度的疫苗。目的是评估截至2022年1月在智利采用三种不同接种方案进行免疫接种后的体液免疫和细胞免疫反应。招募了60名按三剂方案接种的志愿者，他们没有感染史，也未与阳性患者密切接触。检测了针对刺突抗原结构域的IgG，并测量了针对两组变体（原始毒株/阿尔法毒株和贝塔毒株/伽马毒株）的中和能力。最后，通过干扰素释放检测法（IGRA）测量了细胞反应。结果显示，在比较三针Comirnaty疫苗与科兴疫苗和阿斯利康疫苗时，针对原始毒株和阿尔法变体的中和抗体存在显著差异。观察到大量针对不同SARS-CoV-2变体（阿尔法、伽马和德尔塔）的反应性受试者，三种方案之间均无显著差异，证实存在针对SARS-CoV-2的细胞免疫反应。总之，这三种疫苗方案在这些志愿者中产生了细胞免疫反应。
